The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Global Cancer Incidence and Mortality Rates and Trends—An Update
Torre, L. A., Siegel, R. L., Ward, E. M., & Jemal, A. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0578 · Cited by 3,692
Murray, D. D., Suzuki, K., Law, M., Trebicka, J., Neuhaus, J., Wentworth, D., Johnson, M., Vjecha, M. J., Kelleher, A. D., Emery, S., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139981 · Cited by 2,740
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Robert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
The sympathetic nervous system induces a metastatic switch in primary breast cancer
Sloan, E. K., Priceman, S. J., Cox, B. F., Yu, S., Pimentel, M. A., Tangkanangnukul, V., Arevalo, J. M. G., Morizono, K., Karanikolas, B. D. W., Wu, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0522 · Cited by 930
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011418 · Cited by 817
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
De Luca, A., Maiello, M. R., D'Alessio, A., Pergameno, M., & Normanno, N. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.639361 · Cited by 735
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., Schwartz, G. F., Park, P. K., Rosenberg, A. L., Brill, K., et al. (2007) · Cancer · doi:10.1002/cncr.22836 · Cited by 602
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Paplomata, E., & O’Regan, R. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014530023 · Cited by 593
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer
Gao, R., Davis, A., McDonald, T. O., Sei, E., Shi, X., Wang, Y., Tsai, P.-C., Casasent, A., Waters, J., Zhang, H., et al. (2016) · Nature Genetics · doi:10.1038/ng.3641 · Cited by 523
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Melhem-Bertrandt, A., Chavez-MacGregor, M., Lei, X., Brown, E. N., Lee, R. T., Meric-Bernstam, F., Sood, A. K., Conzen, S. D., Hortobagyi, G. N., & Gonzalez-Angulo, A.-M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4441 · Cited by 464
Powe, D. G., Voss, M. J., Zänker, K. S., Habashy, H. O., Green, A. R., Ellis, I. O., & Entschladen, F. (2010) · Oncotarget · doi:10.18632/oncotarget.197 · Cited by 453
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo, H. S., Liu, M. C., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436
Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
Brufsky, A. M., Hurvitz, S., Perez, E., Swamy, R., Valero, V., O'Neill, V., & Rugo, H. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.1255 · Cited by 421
Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F. C., van Kouwenhove, M., Kreike, B., Mackay, A., et al. (2010) · Oncogene · doi:10.1038/onc.2009.489 · Cited by 416
Triple-negative breast cancer: treatment challenges and solutions
Jerusalem, G., Collignon, J., Schroeder, H., & Lousberg, L. (2016) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s69488 · Cited by 385
Vera-Badillo, F. E., Templeton, A. J., de Gouveia, P., Diaz-Padilla, I., Bedard, P. L., Al-Mubarak, M., Seruga, B., Tannock, I. F., Ocana, A., & Amir, E. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt319 · Cited by 370
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Potential role of glutathione in evolution of thiol-based redox signaling sites in proteins
Mohanasundaram, K. A., Haworth, N. L., Grover, M. P., Crowley, T. M., Goscinski, A., & Wouters, M. A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00001 · Cited by 326
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Leo, A. D., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt337 · Cited by 321
Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M.-C., Mills, G. B., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer
Nolan, E., Savas, P., Policheni, A. N., Darcy, P. K., Vaillant, F., Mintoff, C. P., Dushyanthen, S., Mansour, M., Pang, J.-M. B., Fox, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4922 · Cited by 295
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Hu, X., Zhang, J., Xu, B., Jiang, Z., Ragaz, J., Tong, Z., Zhang, Q., Wang, X., Feng, J., Pang, D., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28829 · Cited by 264
The long-term risk of premature mortality in people with epilepsy
Neligan, A., Bell, G. S., Johnson, A. L., Goodridge, D. M., Shorvon, S. D., & Sander, J. W. (2011) · Brain · doi:10.1093/brain/awq378 · Cited by 255
PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
Soliman, H., Khalil, F., & Antonia, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088557 · Cited by 245
Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4032 · Cited by 243
Nuclear EGFR as a molecular target in cancer
Brand, T. M., Iida, M., Luthar, N., Starr, M. M., Huppert, E. J., & Wheeler, D. L. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.010 · Cited by 239
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., Timms, K., Abkevich, V., Schackmann, E. A., Wapnir, I. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0085 · Cited by 233
Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K., Holliday, A., Cooper, C. L., Robbins, E., Gillett, D., et al. (2016) · Histopathology · doi:10.1111/his.12904 · Cited by 231
Genome-wide transcriptome profiling of homologous recombination DNA repair
Peng, G., Chun-Jen Lin, C., Mo, W., Dai, H., Park, Y.-Y., Kim, S. M., Peng, Y., Mo, Q., Siwko, S., Hu, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4361 · Cited by 229
Sihto, H., Lundin, J., Lundin, M., Lehtimäki, T., Ristimäki, A., Holli, K., Sailas, L., Kataja, V., Turpeenniemi-Hujanen, T., Isola, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2944 · Cited by 229
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Finn, R. S., Bengala, C., Ibrahim, N., Roché, H., Sparano, J., Strauss, L. C., Fairchild, J., Sy, O., & Goldstein, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0288 · Cited by 220
SRC: A Century of Science Brought to the Clinic
Aleshin, A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 211
Emens, L. A., Braiteh, F. S., Cassier, P., Delord, J.-P., Eder, J. P., Fasso, M., Xiao, Y., Wang, Y., Molinero, L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211
Impact of Spatial Soil and Climate Input Data Aggregation on Regional Yield Simulations
Hoffmann, H., Zhao, G., Asseng, S., Bindi, M., Biernath, C., Constantin, J., Coucheney, E., Dechow, R., Doro, L., Eckersten, H., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151782 · Cited by 199
Dent, R. A., Lindeman, G. J., Clemons, M., Wildiers, H., Chan, A., McCarthy, N. J., Singer, C. F., Lowe, E. S., Watkins, C. L., & Carmichael, J. (2013) · Breast Cancer Research · doi:10.1186/bcr3484 · Cited by 184
Lee, J.-M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L., Zujewski, J. A., Yu, M., Gordon, N., Ji, J., Sissung, T. M., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju089 · Cited by 184
Yang, M., Kozminski, D. J., Wold, L. A., Modak, R., Calhoun, J. D., Isom, L. L., & Brackenbury, W. J. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2102-9 · Cited by 184
Min, A., Im, S.-A., Kim, D. K., Song, S.-H., Kim, H.-J., Lee, K.-H., Kim, T.-Y., Han, S.-W., Oh, D.-Y., Kim, T.-Y., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0534-y · Cited by 177
Balmaña, J., Tung, N. M., Isakoff, S. J., Graña, B., Ryan, P. D., Saura, C., Lowe, E. S., Frewer, P., Winer, E., Baselga, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu187 · Cited by 177
Costa, R., Shah, A. N., Santa-Maria, C. A., Cruz, M. R., Mahalingam, D., Carneiro, B. A., Chae, Y. K., Cristofanilli, M., Gradishar, W. J., & Giles, F. J. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.12.010 · Cited by 177
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
Eccles, S. A. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.113396se · Cited by 176
Brackenbury, W. J., Chioni, A.-M., Diss, J. K. J., & Djamgoz, M. B. A. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9281-1 · Cited by 175
Self-citationPhase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Tutt, A., Robson, M., Garber, J. E., Domchek, S., Audeh, M. W., Weitzel, J. N., Friedlander, M., & Carmichael, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra501 · Cited by 174
Triple-Negative Breast Carcinoma
Schmadeka, R., Harmon, B. E., & Singh, M. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpqn8gz8silkgn · Cited by 167
Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair
Kumar, A., Fernandez-Capetillo, O., & Carrera, A. C. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914242107 · Cited by 165
Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer.
Giltnane, J. M., & Balko, J. M. (2014) · PubMed · Cited by 164
Finn, R. S., Press, M. F., Dering, J., Arbushites, M., Koehler, M., Oliva, C., Williams, L. S., & Di Leo, A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1925 · Cited by 164
Traina, T. A., Miller, K., Yardley, D. A., O'Shaughnessy, J., Cortes, J., Awada, A., Kelly, C. M., Trudeau, M. E., Schmid, P., Gianni, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.1003 · Cited by 164
Targeting EGFR in Triple Negative Breast Cancer
Ueno, N. T., & Zhang, D. (2011) · Journal of Cancer · doi:10.7150/jca.2.324 · Cited by 161
Ha, K., Fiskus, W. C., Choi, D. S., Bhaskara, S., Cerchietti, L. C. A., Devaraj, S. G. T., Shah, B., Sharma, S., Chang, J. C., Melnick, A. M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2154 · Cited by 161
Tang, J., Li, Z., Lu, L., & Cho, C. H. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.009 · Cited by 160
Gucalp, A., Sparano, J. A., Caravelli, J., Santamauro, J., Patil, S., Abbruzzi, A., Pellegrino, C., Bromberg, J., Dang, C., Theodoulou, M., et al. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.021 · Cited by 159
Teng, Y. H.-F., Tan, W.-J., Thike, A., Cheok, P. Y., Tse, G. M.-K., Wong, N.-S., Yip, G. W. C., Bay, B., & Tan, P. (2011) · Breast Cancer Research · doi:10.1186/bcr2857 · Cited by 154
Gerber, B., Loibl, S., Eidtmann, H., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt361 · Cited by 153
Isakoff, S. J., Overmoyer, B. A., Tung, N., Gelman, R. S., Giranda, V. L., Bernhard, K. M., Habin, K. R., Ellisen, L. W., Winer, E. P., & Goss, P. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1019 · Cited by 152
Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization
Driffort, V., Gillet, L., Bon, É., Marionneau‐Lambot, S., Oullier, T., Joulin, V., Collin, C., Pagès, J., Jourdan, M.-L., Chevalier, S., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-264 · Cited by 142
Stecklein, S. R., Kumaraswamy, E., Behbod, F., Wang, W., Chaguturu, V., Harlan-Williams, L. M., & Jensen, R. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203326109 · Cited by 136
Mo, W., Liu, Q., Lin, C. C.-J., Dai, H., Peng, Y., Liang, Y., Peng, G., Meric‐Bernstam, F., Mills, G. B., Li, K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1772 · Cited by 136
Voltage-gated sodium channels and cancer: is excitability their primary role?
Roger, S., Gillet, L., Guennec, J. L., & Besson, P. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00152 · Cited by 133
Cardillo, T. M., Sharkey, R. M., Rossi, D. L., Arrojo, R., Mostafa, A. A., & Goldenberg, D. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2401 · Cited by 133
Onkal, R., & Djamgoz, M. B. A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.040 · Cited by 128
Self-citationAdams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Molinero, L. L., He, X., Waterkamp, D., Funke, R. P., & Powderly, J. D. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.1009 · Cited by 127
Guerrab, A. E., Bamdad, M., Kwiatkowski, F., Bignon, Y., Penault-Llorca, F. M., & Aubel, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12037 · Cited by 122
Nabholtz, J., Abrial, C., Mouret‐Reynier, M., Dauplat, M.-M., Weber, B. E., Gligorov, J., Forest, A. M., Trédan, O., Vanlemmens, L., Petit, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu183 · Cited by 121
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Tutt, A. N. J., Robson, M. E., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M. L., & Carmichael, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra501 · Cited by 120
Campone, M., Bondarenko, I., Brincat, S., Hotko, Y., Munster, P. N., Chmielowska, E., Fumoleau, P., Ward, R. L., Bardy‐Bouxin, N., Leip, E. P., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr261 · Cited by 114
Gonzalez-Angulo, A. M., Akçakanat, A., Liu, S., Green, M. C., Murray, J. L., Chen, H., Palla, S. L., Koenig, K. B., Brewster, A. M., Valero, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu124 · Cited by 110
Djamgoz, M. B. A., & Onkal, R. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/15748928130107 · Cited by 107
Self-citationAnalysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
Cossu‐Rocca, P., Orrù, S., Muroni, M. R., Sanges, F., Sotgiu, G., Ena, S., Pira, G., Murgia, L., Manca, A., Uras, M. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141763 · Cited by 104
Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells
Liu, T., Yacoub, R., Taliaferro-Smith, L. D., Sun, S., Graham, T. R., Dolan, R. S., Lobo, C., Tighiouart, M., Yang, L. P. H., Adams, A. L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0925 · Cited by 100
EGFR/Met association regulates EGFR TKI resistance in breast cancer
Mueller, K. L., Yang, Z.-Q., Haddad, R., Ethier, S. P., & Boerner, J. L. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-8 · Cited by 99
Choy, C., Raytis, J. L., Smith, D. D., Duenas, M. J., Neman, J., Jandial, R., & Lew, M. W. (2016) · Oncology Reports · doi:10.3892/or.2016.4710 · Cited by 99
Makvandi, M., Xu, K., Lieberman, B. P., Anderson, R., Effron, S. S., Winters, H. D., Zeng, C., McDonald, E. S., Pryma, D. A., Greenberg, R. A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0416 · Cited by 98
Kim, Y. J., Choi, J., Seo, J., Song, J., Lee, S. E., Kwon, M. J., Kwon, M. J., Kundu, J., Jung, K., Oh, E., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28566 · Cited by 97
Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., Rasco, D. W., Jones, S. F., Smith, L. S., Cox, D. S., Durante, M., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.020 · Cited by 93
Djamgoz, M. B. A., & Onkal, R. (2013) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892811308010066 · Cited by 90
Self-citationGrottke, A., Ewald, F., Lange, T., Nörz, D. S., Herzberger, C., Bach, J., Grabinski, N., Gräser, L., Höppner, F., Nashan, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146370 · Cited by 84
Triple-Negative Breast Cancer: Current State of the Art
Rastelli, F., Biancanelli, S., Falzetta, A., Martignetti, A., Casi, C., Bascioni, R., Giustini, L., & Crispino, S. (2010) · Tumori Journal · doi:10.1177/548.6505 · Cited by 73
Brazelle, W., Kreahling, J. M., Gemmer, J. Y., Ma, Y., Cress, W. D., Haura, E. B., & Altiok, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014335 · Cited by 72
Precision medicine in breast cancer: reality or utopia?
Bettaïeb, A., Paul, C., Plenchette, S., Shan, J., Chouchane, L., & Ghiringhelli, F. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1239-z · Cited by 70
Wong, S. W., Tiong, K. H., Kong, W. Y., Yue, Y. C., Chua, C. H., Lim, J. Y., Lee, C. Y., Quah, S. I., Fow, C., Chung, C., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1055-0 · Cited by 69
Proia, D. A., Zhang, C., Sequeira, M., Jimenez, J.-P., He, S., Spector, N. L., Shapiro, G. I., Tolaney, S. M., Nagai, M., Acquaviva, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2166 · Cited by 69
Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
Caiazza, F., Murray, A. M., Madden, S. F., Synnott, N. C., Ryan, E. J., O’Donovan, N., Crown, J. P., & Duffy, M. J. (2016) · Endocrine Related Cancer · doi:10.1530/erc-16-0068 · Cited by 63
XIA, Q., Cai, Y., Peng, R., Wu, G., Shi, Y., & Jiang, W. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2240 · Cited by 62
Hilborn, E., Gacic, J., Fornander, T., Nordenskjöld, B. A., Stål, O., & Jansson, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.464 · Cited by 53
Layman, R. M., Ruppert, A. S., Lynn, M., Mrózek, E., Ramaswamy, B., Lustberg, M. B., Wesolowski, R., Ottman, S., Carothers, S., Bingman, A. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2112-2 · Cited by 48
McArthur, H. L., & Page, D. B. (2016) · PubMed · Cited by 48
Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells
Kim, E. M. H., Mueller, K., Gartner, E. M., & Boerner, J. L. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.06.041 · Cited by 47
González‐Pérez, V., Reiner, D. J., Alan, J. K., Mitchell, C. E., Edwards, L. J., Khazak, V., Der, C. J., & Cox, A. D. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-2 · Cited by 46
Leung, E. Y., Askarian-Amiri, M., Finlay, G. J., Rewcastle, G. W., & Baguley, B. C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131400 · Cited by 45
Speyer, C. L., Nassar, M. A., Hachem, A. H., Bukhsh, M. A., Jafry, W. S., Khansa, R. M., & Gorski, D. H. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3816-x · Cited by 44
EGFR and MEK Blockade in Triple Negative Breast Cancer Cells
Maiello, M. R., D’Alessio, A., Bevilacqua, S., Gallo, M., Normanno, N., & Luca, A. D. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25220 · Cited by 43
Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R
de Lint, K., Poell, J. B., Soueidan, H., Jastrzebski, K., Rodriguez, J. V., Lieftink, C., Wessels, L. F. A., & Beijersbergen, R. L. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0865 · Cited by 43
Immunotherapy Bridge 2016 and Melanoma Bridge 2016: meeting abstracts
Hirsh, V., Pignata, S., Bersanelli, M., Gnetti, L., Azzoni, C., Bottarelli, L., Gasparro, D., Leonardi, F., Silini, E. M., Buti, S., et al. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-016-1095-2 · Cited by 43
Audeh, W. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s39765 · Cited by 42
Ayub, A., Yip, W. K., & Seow, H. F. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.031 · Cited by 39
Anbalagan, M., Moroz, K., Ali, A. M., Carrier, L., Glodowski, S., & Rowan, B. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033017 · Cited by 39
MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells
Kim, S., Lee, J., Jeon, M., Lee, J. E., & Nam, S. J. (2015) · Tumor Biology · doi:10.1007/s13277-015-4345-7 · Cited by 39
Fairhurst, C. M., Watt, I., Martin, F., Bland, M., & Brackenbury, W. J. (2015) · Scientific Reports · doi:10.1038/srep16758 · Cited by 38
Genetically engineered mouse models of PI3K signaling in breast cancer
Klarenbeek, S., van Miltenburg, M. H., & Jonkers, J. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.003 · Cited by 37
Takada, M., Fujimoto, M., Motomura, H., & Hosomi, K. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.13834 · Cited by 37
Fraser, S. P., Foo, I. T. H., & Djamgoz, M. B. A. (2014) · British Journal of Anaesthesia · doi:10.1093/bja/aeu221 · Cited by 36
Self-citationBahnassy, A. A., Mohanad, M., Ismail, M. F., Shaarawy, S., Bastawisy, A. E., & Zekri, A. N. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.07.014 · Cited by 34
Tripathy, D., Chien, A. J., Hylton, N. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.524 · Cited by 31
Sobande, F., Dušek, L., Matějková, A., Rozkoš, T., Laco, J., & Ryška, A. (2015) · PubMed · Cited by 30
Yu, F., ZHAO, J., Hu, Y., Zhou, Y., Guo, R., Bai, J., Zhang, S., Zhang, H., & Zhang, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4799 · Cited by 28
Breast screening interval and the characteristics of screen-detected cancers
Tupper, C. A., Maxwell, A., Astley, S., Bydder, M., Gadde, S., Harkness, E. F., Lim, Y. Y., Wilson, M., & Morris, J. (2015) · Breast Cancer Research · doi:10.1186/bcr3758 · Cited by 27
Clumeck, C., Garcia, S. S., Bourguignon, M., Wens, V., Beeck, M. O. D., Marty, B., Deconinck, N., Soncarrieu, M., Goldman, S., Jousmäki, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092329 · Cited by 17
Rodler, E. T., Gralow, J. R., Kurland, B. F., Griffin, M., Yeh, R. F., Thompson, J. A., Porter, P. L., Swisher, E. M., Gadi, V. K., Korde, L. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2569 · Cited by 15
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Wu, Q., ba-alawi, W., Deblois, G., Cruickshank, J., Duan, S., Lima-Fernandes, E., Haight, J., Tonekaboni, S. A. M., Fortier, A.-M., Kuasne, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18020-8 · Cited by 305
He, J., Peng, T., Peng, Y., Ai, L., Deng, Z., Wang, X.-Q., & Tan, W. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10510 · Cited by 160
Identification of synergistic drug combinations using breast cancer patient-derived xenografts
Turner, T. H., Alzubi, M. A., & Harrell, J. C. (2020) · Scientific Reports · doi:10.1038/s41598-020-58438-0 · Cited by 50
Metadata
- Authors
- Lee, A., & Djamgoz, M. B. A.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 62
- Pages
- 110-122
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2768583786
- Cited by
- 354
- References
- 139
- FWCI
- 12.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.